Allurion Technologies, Inc.(ALUR)
USD --+0.00%
Reward43Moderate
Risk55Medium-High
📊75%Data
Thin -189% profit margin · Revenue down 35% YoY
ALUR
+0.0 · +0.00%
USD · NYSE
Allurion Technologies, Inc. | Healthcare
Value Trap
Market Cap:11.10M
ℹ️
Reward Rating
43
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
55
Medium-High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ALUR to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $5.50.

What is Allurion Technologies, Inc.?

focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally.

ALUR · Verdict

Moderate reward · elevated risk

ALUR stands out on valuation and volatility, but watch the cash flow signal.

Based on 88% data coverage

ALUR · Verdict

What’s working & what to watch

Strengths 2

  • Valuation84/100

    P/E 0.8×

  • Volatility75/100

    Above average

Watchouts 3

  • Cash flow20/100

    -190% free-cash-flow margin

  • Growth29/100

    Rev -38.1% CAGR · earnings -8.7%

  • Profitability32/100

    -189% net margin · 0% ROE

Model-based scoring. For information only — not financial advice.

What is Allurion Technologies, Inc.?

focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 11.10M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (43)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap11.10M
P/E RatioN/A
Dividend YieldN/A
52 Week High3.42
52 Week Low0.23
Last AnnualDecember
IPO Date8/2/2023
IncorporatedUSA
Shares Outstanding15M
No. of Employees38
IndustryMedical Devices
ExchangeNYSE
Beta-0.252
CurrencyUSD